|
End-of-day quote
Korea S.E.
2026-10-23
|
5-day change | 1st Jan Change | ||
| 1,900.00 KRW | -1.04% |
|
-3.80% | -81.83% |
Company Valuation: Aprogen Medicines Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 374,121 | 335,573 | 399,707 | 234,315 | 219,892 | 215,057 |
| Change | - | -10.3% | 19.11% | -41.38% | -6.16% | -2.2% |
| Enterprise Value (EV) 1 | 222,313 | 254,743 | 442,443 | 318,048 | 289,933 | 352,159 |
| Change | - | 14.59% | 73.68% | -28.12% | -8.84% | 21.46% |
| P/E | -7.46x | -18.1x | -3.45x | -4.07x | -3.44x | -2.95x |
| PBR | 1.17x | 1x | 1.86x | 1.59x | 1.39x | 1.36x |
| PEG | - | 0.3x | -0x | 0.1x | 0.76x | -0.62x |
| Capitalization / Revenue | 2.94x | 2.38x | 5.1x | 1.56x | 1.46x | 1.82x |
| EV / Revenue | 1.75x | 1.8x | 5.65x | 2.11x | 1.93x | 2.99x |
| EV / EBITDA | 31.1x | -395x | -5x | -4.83x | -4.39x | -4.89x |
| EV / EBIT | 78.2x | -52x | -3.78x | -3.35x | -3.21x | -3.68x |
| EV / FCF | -4.57x | -1.98x | -3.05x | -14.7x | -6.61x | -3.85x |
| FCF Yield | -21.9% | -50.6% | -32.8% | -6.81% | -15.1% | -26% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -12,334 | -4,193 | -7,461 | -3,540 | -3,379 | -3,540 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 127,143 | 141,247 | 78,349 | 150,578 | 150,114 | 117,974 |
| EBITDA 1 | 7,152 | -644.7 | -88,552 | -65,899 | -66,017 | -71,974 |
| EBIT 1 | 2,844 | -4,902 | -116,944 | -94,970 | -90,322 | -95,571 |
| Net income 1 | -46,490 | -18,002 | -98,657 | -55,619 | -58,079 | -70,202 |
| Net Debt 1 | -151,809 | -80,830 | 42,736 | 83,732 | 70,041 | 137,102 |
| Reference price 2 | 92,025.00 | 75,825.00 | 25,740.00 | 14,400.00 | 11,640.00 | 10,455.00 |
| Nbr of stocks (in thousands) | 4,065 | 4,426 | 15,529 | 16,272 | 18,891 | 20,570 |
| Announcement Date | 3/19/21 | 3/23/22 | 3/27/23 | 3/19/24 | 3/13/25 | 3/23/26 |
1KRW in Million2KRW
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 31.86M | ||
| 28.44x | 5.1x | 18.59x | 0.92% | 111B | ||
| 29.39x | 4.61x | 17.46x | 1.83% | 83.61B | ||
| 29.04x | 3.32x | 19.16x | 0.72% | 63.58B | ||
| 40.86x | 6.38x | 28.14x | 1.87% | 59.56B | ||
| 36.88x | 7.46x | 21.85x | -.--% | 53.59B | ||
| 24x | 4.53x | 15.6x | 2.64% | 33.25B | ||
| 20.68x | 1.77x | 12.74x | 2.27% | 30.08B | ||
| 29.33x | 3.89x | 14.65x | 0.12% | 28.51B | ||
| 21.88x | 3.18x | 13.69x | 1.07% | 26.5B | ||
| Average | 28.94x | 4.47x | 17.99x | 1.27% | 48.98B | |
| Weighted average by Cap. | 30.03x | 4.78x | 18.93x | 1.23% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- A007460 Stock
- Valuation Aprogen Medicines Inc.
Select your edition
All financial news and data tailored to specific country editions
















